Plastoquinonyl decyl triphenylphosphonium

Drug Profile

Plastoquinonyl decyl triphenylphosphonium

Alternative Names: Plastomitin; SkQ-1; SkQ1 eye drops; SkQ1 pill; Visomitin

Latest Information Update: 17 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitotech
  • Class Anti-inflammatories; Benzoquinones; Eye disorder therapies; Neuropsychotherapeutics; Organophosphorus compounds; Small molecules
  • Mechanism of Action Antioxidants; Electron transport chain complex protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Dry eyes
  • Phase I Neurodegenerative disorders
  • Clinical Phase Unknown Unspecified
  • Preclinical Inflammation; Uveitis; Wet age-related macular degeneration

Most Recent Events

  • 16 Nov 2016 Preclinical trials in Wet age-related macular degeneration in Russia (Ophthalmic) (Mitotech pipeline, November 2016)
  • 09 Sep 2016 Mitotech receives patent allowance for Plastoquinonyl decyl triphenylphosphonium in USA
  • 25 Jan 2016 Clinical trials in Undefined indication in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top